Downregulation of TrkA protein expression by miRNA‑92a promotes the proliferation and migration of human neuroblastoma cells

Liao,Weiwei; Zhang,Hao; Feng,Chen; Wang,Tianyou; Zhang,Yan; Tang,Suoqin

doi:10.3892/mmr.2014.2235

Downregulation of TrkA protein expression by miRNA‑92a promotes the proliferation and migration of human neuroblastoma cells

Authors:
- Weiwei Liao
- Hao Zhang
- Chen Feng
- Tianyou Wang
- Yan Zhang
- Suoqin Tang
View Affiliations

Affiliations: Department of Pediatrics, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Pediatrics, The Central Hospital of China Aerospace Corporation, Beijing 100049, P.R. China, Department of Hematology‑Oncology, Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, P.R. China
Published online on: May 13, 2014 https://doi.org/10.3892/mmr.2014.2235
Pages: 778-784

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aims of this study were to investigate the regulation of TrkA protein by micro (mi)RNA‑92a and its effect on the proliferation and migration of human neuroblastoma cells. The BE(2)‑M17 human neuroblastoma cell line was cultured and transfected with either miRNA‑92a mimics or miRNA‑92a inhibitors. The expression levels of miRNA‑92a and TrkA mRNA were detected by quantitative polymerase chain reaction prior and subsequent to transfection. TrkA protein was quantitatively detected by flow cytometry. The proliferation and migration of neuroblastoma cells were examined in vitro by Cell Counting Kit‑8 and Transwell assays. Transfection of BE(2)‑M17 cells with miRNA‑92a mimics produced significantly higher expression levels of miRNA‑92a compared with those in the same cells transfected with negative controls (NCs). Increased proliferation and migration of the cells was also observed. Transfection of BE(2)‑M17 cells with miRNA‑92a inhibitors resulted in significantly lower expression levels of miRNA‑92a when compared with those of the same cells transfected with NCs (P<0.01). This reduction in the miRNA‑92a expression levels was accompanied by reduced proliferation and migration of the cells. The expression levels of TrkA mRNA and protein after 24 h transfection with the miRNA‑92a mimics were significantly reduced when compared with the control (P<0.01). However, the expression levels of TrkA were significantly higher (P<0.01) after 48 h transfection with miRNA‑92a inhibitors when compared with the control. In conclusion, miRNA‑92a promoted the proliferation and migration of human neuroblastoma cells through downregulation of TrkA, which suggested that miRNA‑92a may be a potential target for human neuroblastoma treatment in the future.

View Figures

View References

1	Maris JM, Mosse YP, Bradfield JP, et al: Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 358:2585–2593. 2008. View Article : Google Scholar : PubMed/NCBI
2	Schwab M, Westermann F, Hero B and Berthold F: Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 4:472–480. 2003. View Article : Google Scholar : PubMed/NCBI
3	Alaminos M, Mora J, Cheung NK, et al: Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res. 63:4538–4546. 2003.PubMed/NCBI
4	Mestdagh P, Fredlund E, Pattyn F, et al: MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene. 29:1394–1404. 2010. View Article : Google Scholar : PubMed/NCBI
5	O’Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 435:839–843. 2005.PubMed/NCBI
6	Ma L, Young J, Prabhala H, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 12:247–256. 2010.PubMed/NCBI
7	Welch C, Chen Y and Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Mestdagh P, Boström AK, Impens F, et al: The miR-17–92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell. 40:762–773. 2010.
10	Lovén J, Zinin N, Wahlström T, et al: MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci USA. 107:1553–1558. 2010.PubMed/NCBI
11	Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S and Fukuzawa M: Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 30:1189–1196. 2007.PubMed/NCBI
12	Kogner P, Barbany G, Dominici C, Castello MA, Raschellá G and Persson H: Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 53:2044–2050. 1993.PubMed/NCBI
13	Brodeur GM, Minturn JE, Ho R, et al: Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 15:3244–3250. 2009. View Article : Google Scholar : PubMed/NCBI
14	Valster A, Tran NL, Nakada M, Berens ME, Chan AY and Symons M: Cell migration and invasion assays. Methods. 37:208–215. 2005. View Article : Google Scholar
15	Negrini M, Nicoloso MS and Calin GA: MicroRNAs and cancer - new paradigms in molecular oncology. Curr Opin Cell Biol. 21:470–479. 2009. View Article : Google Scholar : PubMed/NCBI
16	Woo CW, Tan F, Cassano H, Lee J, Lee KC and Thiele CJ: Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer. 50:208–212. 2008. View Article : Google Scholar : PubMed/NCBI
17	Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar
18	Bang-Berthelsen CH, Pedersen L, Fløyel T, Hagedorn PH, Gylvin T and Pociot F: Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes. BMC Genomics. 12:972011. View Article : Google Scholar : PubMed/NCBI
19	Xie SY, Li YJ, Wang PY, Jiao F, Zhang S and Zhang WJ: miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells. Oncol Rep. 23:1693–1700. 2010.PubMed/NCBI
20	Olive V, Jiang I and He L: mir-17–92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol. 42:1348–1354. 2010.
21	Fontana L, Fiori ME, Albini S, et al: Antagomir-17–5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One. 3:e22362008.
22	Fontana L, Pelosi E, Greco P, et al: MicroRNAs 17–5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol. 9:775–787. 2007.
23	Haug BH, Henriksen JR, Buechner J, et al: MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis. 32:1005–1012. 2011. View Article : Google Scholar : PubMed/NCBI
24	Westermark UK, Wilhelm M, Frenzel A and Henriksson MA: The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 21:256–266. 2011. View Article : Google Scholar : PubMed/NCBI
25	Peterson S and Bogenmann E: The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene. 23:213–225. 2004. View Article : Google Scholar : PubMed/NCBI
26	Nakagawara A: Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell. 11:115–124. 1998.PubMed/NCBI
27	Nakagawara A, Arima M, Azar CG, Scavarda NJ and Brodeur GM: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 52:1364–1368. 1992.PubMed/NCBI
28	Kogner P, Barbany G, Dominici C, Castello MA, Raschellá G and Persson H: Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 53:2044–2050. 1993.PubMed/NCBI
29	Nakagawara A: Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 169:107–114. 2001. View Article : Google Scholar : PubMed/NCBI
30	Nakagawara A: The NGF story and neuroblastoma. Med Pediatr Oncol. 31:113–115. 1998. View Article : Google Scholar : PubMed/NCBI
31	Hughes AL, Gollapudi L, Sladek TL and Neet KE: Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. Simultaneous differentiation and proliferation subsequent to p53 functional inactivation. J Biol Chem. 275:37829–37837. 2000. View Article : Google Scholar : PubMed/NCBI
32	Kaplan DR and Miller FD: Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol. 9:213–221. 1997. View Article : Google Scholar : PubMed/NCBI